Latest news with #Primates
Business Wire
30-04-2025
- Business
- Business Wire
Capstan Therapeutics to Participate in Upcoming Scientific Conferences and Present New Preclinical Data in Support of Lead Anti-CD19 In Vivo CAR-T Candidate, CPTX2309
SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. ('Capstan'), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that the Company will present at upcoming scientific conferences and showcase new preclinical data on CPTX2309, Capstan's lead anti-CD19 in vivo CAR-T candidate, at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, LA. 'Among the diverse set of presentations showcasing Capstan's non-viral CellSeeker™ platform, we are particularly encouraged by new preclinical data in support of our in vivo anti-CD19 CAR-T program, which demonstrate that a compact two-dose cycle was sufficient to induce rapid and deep B cell depletion in blood and tissues of non-human primates,' said Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D at Capstan. 'These preclinical data highlight the potency of B cell depletion achievable with a transient in vivo CAR mRNA approach, without the need for lymphodepletion, and set the stage for clinical evaluation of CPTX2309.' Featured Presentation: American Society of Gene & Cell Therapy (ASGCT) 28 th Annual Meeting Date: Location: New Orleans, LA Oral presentation title: A Two-Infusion Regimen with a Novel In Vivo Non-Viral Chimeric Antigen Receptor (CAR) Achieves up to 90% CD8+ T Cell Engineering and Tissue Depletion of Target Cells in Non-Human Primates (NHPs) Presenter: Haig Aghajanian, Ph.D., Vice President of Research, Co-founder Session title: CAR T Innovations in Autoimmune and Infectious Disease and Allergy Date and time: May 15, 2025, 5:00 p.m. - 5:15 p.m. CT Location: Room 393-396 Additional Presentations feature progress with our CellSeeker TM platform technology applicable to both mRNA and gene editing payloads: Cellicon Valley '25: The Future of Cell and Gene Therapies Date: Apr 30-May 2, 2025 Location: Philadelphia, PA Oral Presentation Title: Leading the Charge for In Vivo Cell Therapy for The Treatment of Autoimmune Disorders Presenter: Laura Shawver, Ph.D., Chief Executive Officer Session title: Plenary Session 2, Leadership in Cell and Gene Therapies: The XX Factor Date and Time: May 1, 2025, 10:20 a.m. - 10:30 a.m. ET International Society of Cell & Gene Therapy (ISCT) 2025 Date: May 7-10, 2025 Location: New Orleans, LA Poster title: Design and Preclinical Development of a Novel In Vivo Chimeric Antigen Receptor (CAR) Product for B-Cell Involved Diseases Presenter: Haig Aghajanian, Ph.D., Vice President of Research, Co-founder Poster number: 901 Session title: Poster Networking Reception 1; Immunotherapy (CAR-T, T Reg, NK Cells, etc.) Date and time: May 7, 2025, 7:00 p.m. - 8.30 p.m. CT 21 st Annual PEGS Boston: The Essential Protein & Antibody Engineering Summit Date: May 12-16, 2025 Location: Omni Boston Hotel at the Seaport, Boston, MA Title: Chairperson's Remarks Presenter: Adrian Bot, M.D., Ph.D., Chief Scientific Officer Track: In Vivo CAR T Engineering: Moving into the Clinic Date and time: May 15, 2025, 8:25 a.m. ET Oral presentation title: In vivo mRNA-Based CAR T Cell Engineering for Treatment of B Cell Disorders Presenter: John Rossi, Vice President, Translational Medicine Track: In Vivo CAR T Engineering: Moving into the Clinic Date and time: May 15, 2025, 9:00 a.m. ET American Society of Gene & Cell Therapy (ASGCT) 28 th Annual Meeting Date: May 13-17, 2025 Location: New Orleans, LA Science Symposium: Targeted Nanosystems For Gene Transfer And Editing: Beyond Delivery To The Liver Oral presentation title: In vivo immune cell engineering using targeted nanoparticles Presenter: Priya Karmali, Ph.D., Chief Technology Officer Date and time: May 16, 2025, 4:10 p.m. - 4:35 p.m. CT Location: NOLA Theater B Poster: Efficient In Vivo Gene Editing of T Cells Utilizing Novel Targeted Lipid Nanoparticles Presenter: Esther Chen, Ph.D., Principal Scientist, R&D Session title: Tuesday Poster Reception Date and time: May 13, 2025, 6:00 p.m. - 7:30 p.m. CT Location: Poster Hall I2 Poster: Effective Gene Editing in Hematopoietic Stem and Progenitor Cells (HSPCs) through a Novel Targeted Lipid Nanoparticle Presenter: Esther Chen, Ph.D., Principal Scientist, R&D Session title: Thursday Poster Reception Date and time: May 15, 2025, 5:30 p.m. - 7:00 p.m. CT Location: Poster Hall I2 TIDES USA Date: May 19-22, 2025 Location: Manchester Grand Hyatt San Diego, San Diego, CA Oral presentation title: In Vivo Engineering of Cells Using Targeted Lipid Nanoparticles Presenter: Priya Karmali, Ph.D., Chief Technology Officer Track: mRNA Technology and Applications Date and time: May 21, 2025, 2:00 p.m. PT About Capstan Therapeutics, Inc. ( Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan's CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit and follow us on LinkedIn.
Yahoo
17-04-2025
- Science
- Yahoo
A group of gorillas have a surprising knack for hunting truffles, researchers find
Pigs typically get all of the praise when it comes to sniffing out truffles. However, some birds, a pair of specially trained dogs, and primates are also proving to be quite adept at finding these savory fungi which are a staple of fine dining. Some 'soil scratching' gorillas in Congo's Nouabalé-Ndoki National Park also appear to be foraging for a specific species of truffle and not insects as scientists long believed. The findings are detailed in a study recently published in the journal Primates. An estimated 180 western lowland gorillas have reportedly reside in Nouabalé-Ndoki National Park in the Republic of Congo in Central Africa alongside Elephants and chimpanzees. The over 1,500 square mile lowland rainforest reserve was first established in 1993 and is managed by the Congolese government and Wildlife Conservation Society. Scientists in the park initially believed that the gorillas were searching for insects to eat when they were scratching soil. With local transitional knowledge and molecular classification of the soil, the team observed four groups of gorillas every day for almost 10 years. They eventually succeeded in collecting specimens of the food that the gorillas were foraging for. Taxonomic identification of the food revealed that the gorillas were looking for a specific species of deer truffle (Elaphomyces labyrinthinus). The team believes that this truffle foraging behavior has some important social implications for the primates. While not all of the gorilla groups engage in it, some individuals may give up and take it up again when they move from one group to another. This inter-group movement shows more about their social structure. [ Related: Dogs sniff out two new species of truffle. ] Other primate species have also helped researchers find entirely new species of truffles. In 2020, bonobos in Congo discovered Hysterangium bonobo, a type of fungi that allows trees to absorb key nutrients from the soil and supports the diets of other animals. These new findings were developed by researcher Gaston Abea, of the semi-nomadic indigenous Bangombe people. Abea has been working for the park since 2000 and drew on his traditional knowledge and tracking skills to document this behavior. 'My people's traditional knowledge of these forests is endangered by modern lifestyles but is proving invaluable in continuing to study and preserve these ecosystems,' Abea, who is the lead author of the study, said in a statement. 'Our ancestors used to hunt gorillas, now we protect them, and I hope to inspire other Ba'Akas to do the same.'
